3,4-Methylenedioxymethamphetamine enhances kainic acid convulsive susceptibility

Fecha de publicación

2015-05-13T12:38:54Z

2015-05-13T12:38:54Z

2014-06-28

2015-05-13T12:38:54Z

Resumen

Abstract Kainic acid (KA) causes seizures and neuronal loss in the hippocampus. The present study investigated whether a recreational schedule of 3,4-methylenedioxymethamphetamine (MDMA) favours the development of a seizure state in a model of KA-induced epilepsy and potentiates the toxicity profile of KA (20 or 30 mg/kg). Adolescent male C57BL/6 mice received saline or MDMA t.i.d. (s.c. every 3 h), on 1 day a week, for 4 consecutive weeks. Twenty-four hours after the last MDMA exposure, the animals were injected with saline or KA (20 or 30 mg/kg). After this injection, we evaluated seizures, hippocampal neuronal cell death, microgliosis, astrogliosis, and calcium binding proteins. MDMA pretreatment, by itself, did not induce neuronal damage but increased seizure susceptibility in all KA treatments and potentiated the presence of Fluoro-Jade-positive cells in CA1. Furthermore, MDMA, like KA, significantly decreased parvalbumin levels in CA1 and dentate gyrus, where it potentiated the effects of KA. The amphetamine derivative also promoted a transient decrease in calbindin and calretinin levels, indicative of an abnormal neuronal discharge. In addition, treatment of cortical neurons with MDMA (10<br>50 μM) for 6 or 48 h significantly increased basal Ca2 +, reduced basal Na+ levels and potentiated kainate response. These results indicate that MDMA potentiates KA-induced neurodegeneration and also increases KA seizure susceptibility. The mechanism proposed includes changes in Calcium Binding Proteins expression, probably due to the disruption of intracellular ionic homeostasis, or/and an indirect effect through glutamate release.

Tipo de documento

Artículo


Versión aceptada

Lengua

Inglés

Publicado por

Elsevier B.V.

Documentos relacionados

Versió postprint del document publicat a: http://dx.doi.org/10.1016/j.pnpbp.2014.06.007

Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2014, vol. 54, p. 231-242

http://dx.doi.org/10.1016/j.pnpbp.2014.06.007

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

(c) Elsevier B.V., 2014